Literature DB >> 7769190

Maintenance therapy in ulcerative colitis and Crohn's disease.

D B Sachar1.   

Abstract

Aminosalicylates are of proven benefit in maintaining medically induced remissions of both ulcerative colitis and Crohn's disease. Even rectal 5-aminosalicylic acid has been found to be useful in maintaining long-term remissions of distal ulcerative colitis. Particularly noteworthy is the demonstrated efficacy of oral mesalamine in reducing recurrence rates of Crohn's disease following ileocecal resection, if introduced within the first few weeks after surgery. In all cases, the efficacy of the aminosalicylates is dose related, with little benefit demonstrable, at least in Crohn's disease, at oral doses < 2 g/day. In contrast to aminosalicylates, corticosteroids and cyclosporine are better suited to the induction of rapid remissions of acute disease than to the maintenance of long-term remissions. Antimetabolites, especially azathioprine and 6-mercaptopurine, are highly beneficial and relatively safe for long-term steroid-sparing therapy in both ulcerative colitis and Crohn's disease, at least for those patients whose initial remissions have already been induced by these agents.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769190     DOI: 10.1097/00004836-199503000-00009

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  5 in total

1.  5-ASA Dose-Response: Maximizing Efficacy and Adherence.

Authors:  Seymour Katz; Gary R Lichtenstein; Michael A Safdi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-02

2.  Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.

Authors:  S Schreiber; J Hämling; E Zehnter; S Howaldt; W Daerr; A Raedler; W Kruis
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

3.  Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.

Authors:  G Frieri; R Giacomelli; M Pimpo; G Palumbo; A Passacantando; G Pantaleoni; R Caprilli
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

Review 4.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

5.  Pediatric Inflammatory Bowel Disease.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.